Moderna Inc
MRNA24.770USD
-0.190-0.76%
收盘 11/14, 16:00（美东）报价延迟15分钟
9.69B总市值
亏损市盈率 TTM
关于 Moderna Inc 公司
Moderna, Inc. 是一家生物技术公司。该公司正在开发一种由信使核糖核酸 (mRNA) 制成的新药。该公司正在独立或与战略合作伙伴一起开发用于传染病、免疫肿瘤学、罕见疾病和自身免疫性疾病的疗法和疫苗。mRNA 药物旨在引导人体细胞产生具有治疗或预防益处的细胞内、膜或分泌蛋白，并有可能治疗一系列疾病。其多样化的开发渠道包括 45 个治疗和疫苗项目，其中 9 个处于后期开发阶段。其产品包括 COVID-19 疫苗（mRNA-1273/Spikevax、下一代 mRNA-1283）、RSV 疫苗（mRNA-1345）、季节性流感疫苗（mRNA-1010、mRNA-1011、mRNA-1012、mRNA-1020 和 mRNA-1030）、联合疫苗（mRNA-1083、mRNA-1230、mRNA-1045 和 mRNA-1365）、CMV 疫苗（mRNA-1647）、EBV 疫苗（mRNA-1189 和 mRNA-1195）等。
Moderna Inc简介
公司代码MRNA
公司名称Moderna Inc
上市日期Dec 07, 2018
CEOMr. Stephane Bancel
员工数量5800
证券类型Ordinary Share
年结日Dec 07
公司地址325 Binney Street
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02142
电话16177146500
网址https://www.modernatx.com/
公司代码MRNA
上市日期Dec 07, 2018
CEOMr. Stephane Bancel
Moderna Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
--
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
--
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
28.17K
+2.16%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
18.26K
+4.28%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
--
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Dr. Noubar B. Afeyan, Ph.D.
Dr. Noubar B. Afeyan, Ph.D.
Non-Executive Independent Chairman of the Board, Co-Founder
Non-Executive Independent Chairman of the Board, Co-Founder
--
--
Dr. Rose Loughlin
Dr. Rose Loughlin
Executive Vice President - Research
Executive Vice President - Research
--
--
Mr. Jerh Collins
Mr. Jerh Collins
Chief Technical Operations and Quality Officer
Chief Technical Operations and Quality Officer
--
--
Mr. Stephane Bancel
Mr. Stephane Bancel
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
--
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
--
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
28.17K
+2.16%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
18.26K
+4.28%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
--
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
业务USD
名称
营收
占比
COVID
114.00M
0.00%
RSV
0.00
0.00%
地区USD
名称
营收
占比
United States
88.00M
77.19%
Rest of the World
26.00M
22.81%
Europe
0.00
0.00%
业务
地区
业务USD
名称
营收
占比
COVID
114.00M
0.00%
RSV
0.00
0.00%
股东统计
更新时间: 21 小时前
更新时间: 21 小时前
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
10.52%
Baillie Gifford & Co.
5.59%
BlackRock Institutional Trust Company, N.A.
5.12%
State Street Investment Management (US)
4.38%
Two Sigma Investments, LP
3.66%
其他
70.73%
持股股东
持股股东
占比
The Vanguard Group, Inc.
10.52%
Baillie Gifford & Co.
5.59%
BlackRock Institutional Trust Company, N.A.
5.12%
State Street Investment Management (US)
4.38%
Two Sigma Investments, LP
3.66%
其他
70.73%
股东类型
持股股东
占比
Investment Advisor
38.96%
Investment Advisor/Hedge Fund
14.16%
Hedge Fund
10.34%
Corporation
4.63%
Research Firm
4.51%
Individual Investor
2.54%
Bank and Trust
1.37%
Venture Capital
1.19%
Pension Fund
1.17%
其他
21.14%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
1925
289.85M
74.21%
-20.82M
2025Q2
2015
310.55M
79.82%
-10.63M
2025Q1
2127
325.75M
84.24%
-21.87M
2024Q4
2176
321.41M
83.21%
-6.67M
2024Q3
2154
311.92M
81.18%
-17.40M
2024Q2
2186
316.03M
82.47%
-13.47M
2024Q1
2203
318.24M
83.12%
-1.14M
2023Q4
2309
311.40M
81.63%
+3.41M
2023Q3
2445
301.25M
79.05%
-6.86M
2023Q2
2461
301.15M
78.90%
-7.01M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
41.62M
10.7%
+1.37M
+3.40%
Jun 30, 2025
Baillie Gifford & Co.
22.09M
5.68%
-2.85M
-11.44%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
19.64M
5.05%
+1.76M
+9.86%
Jun 30, 2025
State Street Investment Management (US)
17.27M
4.44%
-507.93K
-2.86%
Jun 30, 2025
Two Sigma Investments, LP
14.77M
3.8%
+6.51M
+78.82%
Jun 30, 2025
Fidelity Management & Research Company LLC
19.46M
5%
-1.37M
-6.56%
Jun 30, 2025
Geode Capital Management, L.L.C.
8.88M
2.28%
+1.42M
+19.05%
Jun 30, 2025
Boston Biotech Ventures, L.L.C.
9.21M
2.37%
+160.31K
+1.77%
Mar 05, 2025
Theleme Partners LLP
7.87M
2.02%
+626.42K
+8.65%
Jun 30, 2025
D. E. Shaw & Co., L.P.
7.46M
1.92%
+1.83M
+32.42%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
iShares Genomics Immunology and Healthcare ETF
3.76%
Global X Genomics & Biotechnology ETF
3.46%
First Trust NYSE Arca Biotechnology Index Fund
2.38%
SPDR S&P Biotech ETF
2.2%
VanEck Biotech ETF
1.84%
Invesco S&P 500 Equal Weight Health Care ETF
1.75%
Langar Global HealthTech ETF
1.61%
Virtus LifeSci Biotech Products ETF
1.57%
ROBO Global Healthcare Technology & Innovation ETF
1.55%
WisdomTree BioRevolution Fund
1.42%
查看更多
iShares Genomics Immunology and Healthcare ETF
占比3.76%
Global X Genomics & Biotechnology ETF
占比3.46%
First Trust NYSE Arca Biotechnology Index Fund
占比2.38%
SPDR S&P Biotech ETF
占比2.2%
VanEck Biotech ETF
占比1.84%
Invesco S&P 500 Equal Weight Health Care ETF
占比1.75%
Langar Global HealthTech ETF
占比1.61%
Virtus LifeSci Biotech Products ETF
占比1.57%
ROBO Global Healthcare Technology & Innovation ETF
占比1.55%
WisdomTree BioRevolution Fund
占比1.42%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
